Alkermes plc: Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four

Related Keywords

Athlone ,Westmeath ,Ireland ,Canada ,Ohio ,United States ,Massachusetts ,Innisfree ,Sligo ,Dublin ,Waltham ,David Amsellem ,Richardb Gaynor ,Gewinn Nur ,Sandy Coombs ,Christopheri Wright ,Marc Goodman ,Akash Tewari ,Piper Sandler ,Davida Daglio ,Emily Peterson Alva ,Katie Joyce ,Nancyj Wysenski ,Chris Kittredge Zachary Tramonti ,Shanem Cooke ,Jessica Fye ,Brianp Mckeon ,Chris Shibutani ,Catot Laurencin ,Johnson ,Company Has Outperformed Peers ,Incyte Corporation ,Nasdaq ,Ironwood Pharmaceuticals Inc ,Company Annual Report On Form ,Drug Administration ,Ionis Pharmaceuticals Inc ,Oncology Development Pipeline ,Financial Operating Committee Of The Board ,Alkermes ,Goldman Sachs ,Company Or Alkermes ,Corporate Governance Committee ,Innisfree Ma Incorporated ,Jp Morgan ,Acadia Pharmaceuticals Inc ,Corporate Governance Committee Of The Board ,Sarepta Therapeutics Inc ,Therapeutics Inc ,Alnylam Pharmaceuticals Inc ,Neurocrine Biosciences Inc ,United Therapeutics Corporation ,Exelixis Inc ,Emergent Biosolutions Inc ,Exchange Commission ,Blueprint Medicines Corporation ,Jazz Pharmaceuticals ,Ultragenyx Pharmaceutical Inc ,Sage Therapeutics Inc ,Nominees On Company ,Relevant Indices Since Unveiling ,Enhancement Plan ,Independent Directors Have Been Appointed Over ,Last Four Years ,Including Four Directors Designated ,Providing Additional Information ,Board Recommends Shareholders Vote ,Director Nominees ,General Meeting ,Annual Meeting ,Value Enhancement Plan ,Sarissa Capital Management ,Elliott Advisors ,United Kingdom ,Financial Operating Committee ,Lead Independent Director ,Peterson Alva ,Alkermes Shareholder ,Annual General Meeting ,Alkermes Board ,Lead Independent ,Plurality Voting ,Ncontested Elections ,Extraordinary General Meeting ,Executive Compensation Programs ,Public Company Boards ,Which Directors May Serve ,Proprietary Commercial Product ,Oncology Development ,Mural Oncology ,Alkerme Board ,Private Securities Litigation Reform Act ,Annual Report ,Additional Information ,Information Regarding Participants ,Alnylam Pharmaceuticals ,Horizon Therapeutics ,Ionis Pharmaceuticals ,Ironwood Pharmaceuticals ,Neurocrine Biosciences ,Sage Therapeutics ,Sarepta Therapeutics ,United Therapeutics ,Files ,Efinitive ,Proxy ,Statement ,Issues ,Setter ,Shareholders ,Retailing ,Business ,Execution ,Hat ,Riven ,Strong ,Performance ,Elivered ,Shareholder ,Value ,